Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
A Single-centre, Open-label, Non-controlled, Exploratory Safety and Efficacy Clinical Trial of GT08 in Volunteers and Patients Who Are Infected With Helicobacter Pylori
Sponsor: Singapore General Hospital
Terminated
Poor efficacy (2 of 31 completing participants with H.pylori eradication)
Other terminated trials from Singapore General Hospital
Other Helicobacter Pylori Infection trials with similar outcome
Listed as NCT01109381, this PHASE1/PHASE2 trial focuses on Helicobacter Pylori Infection and remains terminated or withdrawn. Sponsored by Singapore General Hospital, it has been updated 8 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Singapore General Hospital
- Synergy Pharmaceuticals Pte. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .